BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
A study, phase III, randomized, single-center, of regarding the non-inferiority of the
Medication BL3000, when compared to Pantogar® in the treatment of telogen effluvium in women.
Research product: BL3000. Reference product: Pantogar® List of Study Center: MAIN
INVESTIGATOR STUDY CENTER FONE Medcin Skin Institute Sérgio Schalka 11 36835357